Henning Burmeister

Adherence to ESMO clinical recommendations for prophylaxis of chemotherapy-induced nausea and vomiting

Henning Burmeister, Stefan Aebi, Cristina Studer et al. · Supportive Care in Cancer · 2011 · 65 citations · Full text

Medicine, Oncology, Chemotherapy +11

SAKK 19/17: safety analysis of first-line durvalumab in patients with PD-L1 positive, advanced nonsmall cell lung cancer and a performance status of 2

Michael Mark, Patrizia Froesch, E.I. Eboulet et al. · Cancer Immunology Immunotherapy · 2020 · 18 citations · Full text

Medicine, Oncology, Pharmacology +16

Incidence of hypocalcemia in patients with castration-resistant prostate cancer treated with denosumab: Data from a non-inferiority phase III trial assessing prevention of symptomatic skeletal events (SSE) with denosumab administered every four weeks (q4w) versus every 12 weeks (q12w)—SAKK 96/12 (REDUSE).

Silke Gillessen, R.A.F. von Moos, Stefanie Hayoz et al. · Journal of Clinical Oncology · 2019 · 12 citations

Medicine, Oncology, Pharmacotherapy +13